ProtectH2H: Protect the Head to Head Study
Study Details
Study Description
Brief Summary
Prospective, randomized, open label, multicenter, 2-arm, safety and efficacy study
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
Phase 2 |
Detailed Description
Prospective, randomized, open label, multicenter, 2-arm, safety and efficacy study to demonstrate safety and effectiveness based on non-inferiority of the study device (Emboliner EPD) compared to the control device (Sentinel CPS) in terms of a 30-day composite major adverse cardiac and cerebrovascular events (MACCE) rate - defined as all death, stroke and Stage 3 acute kidney injury - evaluated on a per-patient basis, post-TAVR procedures
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
Experimental: Emboliner Embolic Protection Device Emboliner embolic protection device to be used during TAVR procedures for stroke prevention |
Device: Emboliner Embolic Protection
Emboliner Embolic Protection Device will be used to capture and remove embolic material during transcatheter aortic valve replacement (TAVR) interventions
Other Names:
|
Active Comparator: Sentinel Cerebral Protection System Sentinel Cerebral Protection System to be used during TAVR procedures for stroke prevention |
Device: Sentinel Cerebral Protection
The Sentinel Cerebral Protection System will be used to capture and remove embolic material during transcatheter aortic valve replacement (TAVR) interventions
Other Names:
|
Outcome Measures
Primary Outcome Measures
- Non-inferiority [Non-inferiority of 30-day Emboliner device MACCE patient incidence rate compared to the Sentinel device patient incidence rate.]
Non-inferiority of 30-day Emboliner device MACCE patient incidence rate compared to the Sentinel device patient incidence rate. K4: Description Non-inferiority of 30-day Emboliner device MACCE patient incidence rate compared to the Sentinel device patient incidence rate. 30 Days
Secondary Outcome Measures
- Non-inferiority VARC-2 [30 Days]
Non-inferiority of 30-day Emboliner device VARC 2-defined stroke incidence rate compared to the Sentinel device incidence rate.
- Debris Capture [30 Days]
The count (by number of particles >150 microns) of debris capture using the Emboliner device will be compared to the count of debris captured by the Sentinel device.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Eligible for treatment for symptomatic severe aortic stenosis using a FDA-approved TAVR valve according to current guidelines
-
Consented to the TAVR procedure
-
Subject and physician agree that subject will return for required post-procedure follow-up
-
Willing to participate in study and provide signed EC/IRB-approved informed consent
-
Eighteen (18) years or older at the time of consent
Exclusion Criteria:
-
Not undergoing a planned TAVR via transfemoral access
-
Severe allergy or hypersensitivity to aspirin, heparin or bivalirudin, clopidogrel or ticlopidine, nitinol, and/or contrast agents that cannot be pre-medicated
-
Uncorrected bleeding disorder
-
Hypercoagulation status that cannot be corrected by additional peri-procedural heparin
-
Myocardial infarction (MI) diagnosis <30 days prior to study procedure
-
History of substance abuse that may cause non-compliance with the protocol or confound the data interpretation
-
Cardiogenic shock, hemodynamic instability requiring inotropic support or mechanical heart assistance, or severe hypotension (systolic blood pressure <90 mmHg) at time of screening
-
History of a stroke < 180 days prior to study procedure
-
Active peptic ulcer or history of upper gastrointestinal (GI) bleeding < 90 days prior to study procedure
-
Congenital unicuspid aortic valve
-
Porcelain aorta, asymmetrical or sharp aortic calcifications, severe aortic tortuosity, shaggy aorta or mobile atheroma in the arch
-
Pre-existing prosthetic heart valve in any position, prosthetic ring, or severe (greater than 3+) mitral insufficiency
-
Current leukopenia, acute anemia, thrombocytopenia, history of chronic bleeding diathesis, or coagulopathy that requires treatment
-
Hypertrophic cardiomyopathy with or without obstruction
-
Left ventricular ejection fraction (LVEF) ≤20%
-
Echocardiographic evidence of intracardiac or aortic mass, thrombus, or vegetation
-
Active infection or endocarditis
-
Neurodegenerative or other progressive neurological disease or history of significant head trauma followed by persistent neurologic defaults
-
Carotid stent placement or endarterectomy performed <180 days prior to study procedure.
-
Severe renal insufficiency (creatinine >3.0 mg/dL or GFR <30 mL/min) or patient on dialysis
-
Planned treatment with another investigational device or procedure during the study period
-
Balloon valvuloplasty (BAV) within 30 days of the procedure
-
Any planned surgical or interventional cardiac procedure (e.g., concurrent coronary revascularization or AF ablation) during the TAVR procedure, within 30 days before or after the TAVR procedure
-
Emergency surgery for any reason
-
Pregnancy, lactation or intent to become pregnant during study participation
-
Unable or unwilling to complete all required screening and/or follow-up assessments, including subjects with active major psychiatric disease; with severe visual, auditory, or learning impairment
-
Investigator considers participation in the study not to be in the subject's best interest
-
Dementia or any other cognitive deficit that results in inability to provide informed consent or comply with the study protocol
-
Presence of hemodialysis shunt, graft, or arterio-venous fistula involving access vasculature
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- Emboline
Investigators
- Study Director: Laura A Brenton, Emboline, Inc.
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- TP-0527